Details
Sarcopenia
2. Aufl.
|
139,99 € |
|
| Verlag: | Wiley-Blackwell |
| Format: | EPUB |
| Veröffentl.: | 15.06.2021 |
| ISBN/EAN: | 9781119597902 |
| Sprache: | englisch |
| Anzahl Seiten: | 464 |
DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.
Beschreibungen
<b>SARCOPENIA</b> <p><b>An in-depth examination of sarcopenia’s underexplored yet widespread impact within the field of gerontology</b><p>Sarcopenia is common in older men and women, and yet awareness of its clinical relevance is still relatively low. Only formally included in the International Classification of Diseases in 2016, the condition may impact societies with serious health-related and financial consequences unless consistent, effective methods of identification and management are adopted.<p>This second edition of <i>Sarcopenia</i> provides geriatricians and other healthcare professionals with a revised and expanded examination of this understudied and underdiagnosed condition. Edited by two leading authorities on the subject, it covers the epidemiology and diagnosis of sarcopenia, as well as treatment options and possible prevention strategies. Eight newly written chapters build upon existing knowledge with fresh data on topics including sarcopenia’s biomarkers and its impact on the healthcare economy. This important text: <ul><li>Defines sarcopenia and explains its clinical relevance</li><li>Covers all recent scientific evidence</li><li>Outlines treatment options</li><li>Considers prevention strategies</li><li>Discusses sarcopenia as a public health priority</li><li>Features eight new chapters covering topics such as sarcopenia’s clinical management, its biomarkers, and its financial impact </li></ul><p>Containing vital information for clinicians and other professionals working in geriatric care, nursing homes, nutrition, cancer, endocrinology, surgery, sports medicine and many other specialties, <i>Sarcopenia</i>, second edition, is a groundbreaking and essential new resource.
<p>List of Contributors vii</p> <p>Preface xiii</p> <p>1 Definitions of Sarcopenia 1<br /><i>Alfonso J. Cruz‐Jentoft, Beatriz Montero‐Errasquin and John E. Morley</i></p> <p>2 Epidemiology of Muscle Mass Loss with Age 11<br /><i>Marjolein Visser</i></p> <p>3 The Role of Mitochondria in Age‐Related Sarcopenia 19<br /><i>Luigi Ferrucci, Marta Zampino, Paul Coen and Bret H. Goodpaster</i></p> <p>4 Motor Unit Remodeling 35<br /><i>Ben Kirk and Mathew Piasecki</i></p> <p>5 Nutrition, Protein Turnover and Muscle Mass 45<br /><i>St</i><i>éphane Walrand, Christelle Guillet and Yves Boirie</i></p> <p>6 Recognizing Persons at Risk for Sarcopenia 63<br /><i>John E. Morley</i></p> <p>7 Adverse Outcomes and Functional Consequences of Sarcopenia 71<br /><i>Jean Woo</i></p> <p>8 A Lifecourse Approach to Sarcopenia 77<br /><i>Richard Dodds and Avan Aihie Sayer</i></p> <p>9 Acute Sarcopenia 95<br /><i>Beatrice Gasperini, Stefano Volpato and Antonio Cherubini</i></p> <p>10 Sarcopenia, Frailty, and Intrinsic Capacity 115<br /><i>Jurgen M. Bauer and Cornel Sieber</i></p> <p>11 Osteosarcopenia 127<br /><i>Ben Kirk, Jesse Zanker, Steven Phu and Gustavo Duque</i></p> <p>12 Sarcopenic Obesity 147<br /><i>Mauro Zamboni, Federica Macchi, Nicole Nori and Andrea P. Rossi</i></p> <p>13 Sarcopenia and Cognitive Impairment 157<br /><i>Liang‐Kung Chen</i></p> <p>14 Sarcopenia and Other Chronic Organ Diseases 175<br /><i>Hidenori Arai</i></p> <p>15 Imaging of Skeletal Muscle 185<br /><i>Thomas F. Lang</i></p> <p>16 Measurements of Muscle Mass, Equations and Cut‐off Points 199<br /><i>Marjolein Visser and Laura Schaap</i></p> <p>17 Deuterated Creatine Dilution to Assess Muscle Mass (D3‐Cr Muscle Mass) in Humans: Methods, Early Results, and Future Directions 227<br /><i>Peggy M. Cawthon and William J. Evans</i></p> <p>18 Measurement of Muscle Strength and Power 239<br /><i>Michael Drey, Sandra Helmers and J</i><i>ürgen M. Bauer</i></p> <p>19 Measurements of Physical Performance 253<br /><i>Laura Orlandini, Yves Rolland and Matteo Cesari</i></p> <p>20 Biomarkers for Physical Frailty and Sarcopenia: A “Two‐Body Problem” 271<br /><i>Anna Picca, Riccardo Calvani and Emanuele Marzetti</i></p> <p>21 Quality of Life and Sarcopenia 279<br /><i>Charlotte Beaudart, Jean‐Yves Reginster, Olivier Bruy</i><i>ère and Anton Geerinck</i></p> <p>22 Exercise Interventions to Prevent and Improve Sarcopenia 305<br /><i>Mark D. Peterson and Jose A. Serra</i></p> <p>23 Nutritional Approaches to Treat Sarcopenia 335<br /><i>Tommy Cederholm, Jurgen M. Bauer and Alfonso J. Cruz‐Jentoft</i></p> <p>24 Beta‐hydroxy‐beta‐methylbutyrate (HMB) and Sarcopenia 355<br /><i>Francesco Landi, Riccardo Calvani, Anna Picca and Emanuele Marzetti</i></p> <p>25 The Future of Drug Treatments 367<br /><i>Francesco Landi, Graziano Onder and Rolland Yves</i></p> <p>26 Sarcopenia: Is It Preventable? 403<br /><i>Stany Perkisas, Keliane Liberman, Ivan Bautmans and Maurits Vandewoude</i></p> <p>27 Financial Impact of Sarcopenia 421<br /><i>Kristina Norman</i></p> <p>28 Sarcopenia Management for Clinicians 433<br /><i>Renuka Visvanathan and Solomon Yu</i></p> <p>Index 441</p>
<p><b>Alfonso J. Cruz-Jentoft, MD,</b> Professor, Geriatrics, Universidad Europea de Madrid, and Director of Geriatric Medicine, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain.</p> <p><b>John E. Morley, MD,</b> Professor, Geriatrics, St Louis University Medical School, St Louis, MO, USA.</p>
<p><b>An in-depth examination of sarcopenia's underexplored yet widespread impact within the field of gerontology</b></p> <p>Sarcopenia is common in older men and women, and yet awareness of its clinical relevance is still relatively low. Only formally included in the International Classification of Diseases in 2016, the condition may impact societies with serious health-related and financial consequences unless consistent, effective methods of identification and management are adopted.</p> <p>This second edition of <i>Sarcopenia</i> provides geriatricians and other healthcare professionals with a revised and expanded examination of this understudied and underdiagnosed condition. Edited by two leading authorities on the subject, it covers the epidemiology and diagnosis of sarcopenia, as well as treatment options and possible prevention strategies. Eight newly written chapters build upon existing knowledge with fresh data on topics including sarcopenia's biomarkers and its impact on the healthcare economy. This important text:</p> <ul> <li>Defines sarcopenia and explains its clinical relevance</li> <li>Covers all recent scientific evidence</li> <li>Outlines treatment options</li> <li>Considers prevention strategies</li> <li>Discusses sarcopenia as a public health priority</li> <li>Features eight new chapters covering topics such as sarcopenia’s clinical management, its biomarkers, and its financial impact</li> </ul> <p>Containing vital information for clinicians and other professionals working in geriatric care, nursing homes, nutrition, cancer, endocrinology, surgery, sports medicine and many other specialties, <i>Sarcopenia</i>, second edition, is a groundbreaking and essential new resource.</p>
Diese Produkte könnten Sie auch interessieren:
